Clinical Trial Search

Primary: Percentage of Participants in Remission at Week 10 With Etrolizumab as Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28948 Population — 6.9…

Primary: Acute Effect of a rTMS Session on the Performance for a Working Memory Task, as Measured by Accuracy (in Percentage) — 50.43; 55.42; 83.93; 46.49 percentage of accuracy

Primary: Number of Participants Who Completed a Successful Intervention With No Major Adverse Events — 10 Participants

Primary: Change From Baseline in Adapted Mayo Score (MCS) at Week 12 — -1.94; -2.49; -1.50 score on a scale — p== 0.0091

Primary: Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16…

Primary: Plasma Catecholamine Levels (Maximum Concentration, Cmax) — 218; 394; 290 pg/ml

Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm

Primary: Change in Vibration Frequency Detection Threshold (When Vibration is First Felt) After IM Injection — 22; 21 Hz — p=0.83

Primary: Personal Preventative Behaviors to Decrease Risk of COVID-19 Exposure — 114; 112; 114; 109 Participants

Primary: Change in Geometric Mean Titre Ratio, A/H1N1 Strain — 3.13; 3.17 Ratio of Day 0 and Day 21-28 titres

Primary: Overall Survival (OS) After Initiation of Second Line Sunitinib Therapy — 15.6 Months

Primary: Bioavailability — 1.95; 1.80; 3.00; 0.80 mol%

Primary: Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15) — -13.58; -8.91 score on a scale

Primary: Apnea-Hypopnea Index — 4.1; 3.6 episodes/hour

Primary: Change in Serum Testosterone Levels Between Baseline and After Preoperative Radiotherapy. — 11.3; 11.9; 9.3 nmol/L — p=0.014